Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors

The purpose of this study to investigate the safety and efficacy of using nivolumab to treat subjects who have virus-associated tumors. Certain viruses that infect human cells have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drug nivolumab in human subjects who have the following types of viral-associated tumors: Gastric Cancer, nasopharyngeal carcinoma , cervical cancer, vaginal cancer, vulvar cancer, squamous cell carcinoma of the head and neck, and Merkel Cell Carcinoma.

Inclusion Criteria:

* Histopathologic confirmation of the following tumor types:
Merkel Cell Carcinoma
Gastric or Gastro-Esophageal junction carcinoma
Nasopharyngeal Carcinoma
Squamous cell carcinoma of the cervix, vagina, or vulva
Squamous cell carcinoma of the Head and Neck

* Measurable disease by CT or MRI
Phase I/II
Multiple Tumor Types
Rom Leidner, M.D.
BMS (Bristol-Myers Squibb)
Kim Sutcliffe
  • Oncology and Hematology Care Eastside
  • Oncology and Hematology Care Westside